Cargando…

Therapeutic siRNA targeting endothelial KDR decreases portosystemic collateralization in portal hypertension

Development of portosystemic collateral vessels and gastroesophageal varices is responsible for the most serious clinical consequences of portal hypertension, but effective clinical therapies are limited. Here we developed and investigated the therapeutic potential of an innovative liposomally-formu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gallego, Javier, Garcia-Pras, Ester, Mejias, Marc, Pell, Nuria, Schaeper, Ute, Fernandez, Mercedes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5665956/ https://www.ncbi.nlm.nih.gov/pubmed/29093528 http://dx.doi.org/10.1038/s41598-017-14818-7

Ejemplares similares

Portal Vein/Aorta Ratio in Dogs with Acquired Portosystemic Collaterals
por: Sakamoto, Y., et al.
Publicado: (2017)

Portal hypertension: Imaging of portosystemic collateral pathways and associated image-guided therapy
por: Bandali, Murad Feroz, et al.
Publicado: (2017)

The somatostatin analogue octreotide inhibits angiogenesis in the earliest, but not in advanced, stages of portal hypertension in rats
por: Mejias, Marc, et al.
Publicado: (2008)

Acquired portosystemic collaterals: anatomy and imaging
por: Leite, Andréa Farias de Melo, et al.
Publicado: (2016)

The Role of VEGF and KDR Polymorphisms in Moyamoya Disease and Collateral Revascularization
por: Park, Young Seok, et al.
Publicado: (2012)

Characterization of uncommon portosystemic collateral circulations in patients with hepatic cirrhosis
por: WU, QIN, et al.
Publicado: (2015)

Plasma renin activity and aldosterone concentration in dogs with acquired portosystemic collaterals
por: Sakamoto, Yumi, et al.
Publicado: (2019)

Sleep Disturbance Is Associated With the Presence of Portosystemic Collaterals in Patients With Compensated Cirrhosis
por: Balakrishnan, Maya, et al.
Publicado: (2021)

Computed tomography evaluation of patent paraumbilical vein and its aneurysm in relation to other portosystemic collateral channels in patients with liver cirrhosis and portal hypertension
por: Januszewicz, Magdalena Maria, et al.
Publicado: (2019)

SLN124, a GalNAc-siRNA Conjugate Targeting TMPRSS6, Efficiently Prevents Iron Overload in Hereditary Haemochromatosis Type 1
por: Altamura, Sandro, et al.
Publicado: (2019)

Transjugular Intrahepatic Portosystemic Shunt for the Treatment of Portal Hypertension in Noncirrhotic Patients with Portal Cavernoma
por: Luo, Xuefeng, et al.
Publicado: (2014)

A Comprehensive Review of Portosystemic Collaterals in Cirrhosis: Historical Aspects, Anatomy, and Classifications
por: Philips, Cyriac Abby, et al.
Publicado: (2016)

Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension
por: Tripathi, Dhiraj, et al.
Publicado: (2020)

Blood ammonia levels in liver cirrhosis: a clue for the presence of portosystemic collateral veins
por: Tarantino, Giovanni, et al.
Publicado: (2009)

The Transjugular Intrahepatic Portosystemic Shunt in the Treatment of Portal Hypertension: Current Status
por: Pomier-Layrargues, Gilles, et al.
Publicado: (2012)

Asymptomatic presentation of a congenital malformation of the portal vein with portosystemic shunt
por: Musa, Juna, et al.
Publicado: (2020)

Vasoactive intestinal peptide in canine portosystemic shunt in the absence of portal hypertension
por: Isaka, Mitsuhiro, et al.
Publicado: (2021)

Role of VEGF signalling in the regulation of KDR expression in endothelial and tumoral microenvironment
por: Serpa, Jacinta, et al.
Publicado: (2010)

Enzyme-triggered PEGylated siRNA-nanoparticles for controlled release of siRNA
por: Yingyuad, Peerada, et al.
Publicado: (2014)

Thermal Stability of siRNA Modulates Aptamer- conjugated siRNA Inhibition
por: Berezhnoy, Alexey, et al.
Publicado: (2012)

Where should siRNAs go: applicable organs for siRNA drugs
por: Ahn, Insook, et al.
Publicado: (2023)

Hsp70 Knockdown by siRNA Decreased Collagen Production in Keloid Fibroblasts
por: Shin, Jung U, et al.
Publicado: (2015)

Transsplenic portal vein reconstruction–transjugular intrahepatic portosystemic shunt in a patient with portal and splenic vein thrombosis
por: Salsamendi, Jason T., et al.
Publicado: (2016)

Application of transmesenteric vein extrahepatic portosystemic shunt in treatment of symptomatic portal hypertension with cavernous transformation of portal vein
por: Li, Weixiao, et al.
Publicado: (2023)

Transjugular Intrahepatic Portosystemic Shunt Versus Surgical Shunting in the Management of Portal Hypertension
por: Huang, Long, et al.
Publicado: (2015)

Transjugular intrahepatic portosystemic shunt via left hepatic – left portal veins
por: Maleux, Geert
Publicado: (2019)

The role of transjugular intrahepatic portosystemic shunt in patients with portal hypertension: Advantages and pitfalls
por: Lee, Hae Lim, et al.
Publicado: (2022)

Advanced portal venous access techniques for transjugular intrahepatic portosystemic shunt placement
por: Partovi, Sasan, et al.
Publicado: (2021)

Acquired Portosystemic Shunts in Cirrhosis and Portal Vein Thrombosis: A Case Report
por: Durgham, Anthony, et al.
Publicado: (2022)

Transjugular intrahepatic portosystemic shunt for pediatric portal hypertension: A meta-analysis
por: Raissi, Driss, et al.
Publicado: (2023)

SLN124, a GalNac‐siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron‐overload in a mouse model of β‐thalassaemia
por: Vadolas, Jim, et al.
Publicado: (2021)

Difference between type 2 gastroesophageal varices and isolated fundic varices in clinical profiles and portosystemic collaterals
por: Song, Yu-Hu, et al.
Publicado: (2022)

Transjugular intrahepatic portosystemic shunt for the treatment of portal hypertensive biliopathy with cavernous transformation of the portal vein: a case report
por: Zhao, Ming, et al.
Publicado: (2022)

Transjugular intrahepatic portosystemic shunt with radioactive seed strand for main portal vein tumor thrombosis with cirrhotic portal hypertension
por: Yan, Xuan-Hui, et al.
Publicado: (2022)

Tolerated wobble mutations in siRNAs decrease specificity, but can enhance activity in vivo
por: Holen, Torgeir, et al.
Publicado: (2005)

Liver progenitor cell and KDR
por: Han, Songyan, et al.
Publicado: (2014)

Targeted Delivery of siRNA
por: Oliveira, Sabrina, et al.
Publicado: (2006)

siRNA for Influenza Therapy
por: Barik, Sailen
Publicado: (2010)

Retrovirus-delivered siRNA
por: Devroe, Eric, et al.
Publicado: (2002)

Dendrimers for siRNA Delivery
por: Biswas, Swati, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_3kufvvo6m8c28itnd5ls8qif5s